MINDBIO THERAPEUTICS BEGINS DOSING MB22001 IN PHASE 2 CLINICAL TRIAL IN WORLD FIRST TAKE-HOME MICRODOSING STUDY IN PATIENTS WITH DEPRESSION World-first take-home approvals...
MINDBIO THERAPEUTICS BREAKTHROUGH DISCOVERY IN MICRODOSING CLINICAL TRIAL REVEALS SIGNIFICANT POSITIVE EFFECTS ON QUALITY OF SLEEPNew Discovery: MindBio's LSD-Microdosing Treatment Improves...
MINDBIO THERAPEUTICS CEO DEMONSTRATES HOW 1 MILLION MICRODOSES OF LSD CAN POTENTIALLY BE USED TO TREAT DEPRESSION 1 Million Microdoses used to create proprietary microdosing...
ETHICS APPROVAL FOR LANDMARK WORLD FIRST PHASE 2 CLINICAL TRIAL OF TAKE-HOME LSD-MICRODOSING FOR MAJOR DEPRESSIVE DISORDEREthics approval received for take-home LSD-Microdosing clinical...
PHASE 2 CLINICAL TRIAL HAS RECEIVED ETHICS APPROVAL FOR WORLD FIRST TAKE-HOME LSD-MICRODOSING TRIALS IN CANCER PATIENTS EXPERIENCING EMOTIONAL DISTRESSEthics approval granted The clinical trial...
MindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy Participants MindBio clinical trial...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -28.5714285714 | 0.035 | 0.035 | 0.025 | 31725 | 0.03115654 | CS |
4 | -0.02 | -44.4444444444 | 0.045 | 0.05 | 0.025 | 40226 | 0.03454091 | CS |
12 | -0.03 | -54.5454545455 | 0.055 | 0.07 | 0.025 | 46089 | 0.04584665 | CS |
26 | -0.03 | -54.5454545455 | 0.055 | 0.085 | 0.015 | 52084 | 0.04341007 | CS |
52 | -0.535 | -95.5357142857 | 0.56 | 0.56 | 0.015 | 66537 | 0.06541009 | CS |
156 | -0.535 | -95.5357142857 | 0.56 | 0.56 | 0.015 | 66537 | 0.06541009 | CS |
260 | 0 | 0 | 0 | 0.03 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.